Vemurafenib Active in Progressive, RAI-refractory Papillary Thyroid Cancer

Share this content:
Vemurafenib showed activity in patients with progressive BRAFV600E mutation-positive papillary thyroid cancer refractory to radioactive iodine.
Vemurafenib showed activity in patients with progressive BRAFV600E mutation-positive papillary thyroid cancer refractory to radioactive iodine.

Vemurafenib showed activity in patients with progressive BRAFV600E mutation-positive papillary thyroid cancer refractory to radioactive iodine, who had not previously received a multikinase inhibitor, according to a phase 2 study published in the journal The Lancet Oncology.1

Approximately half of patients diagnosed with papillary thyroid cancer have BRAF V600E mutations. Vemurafenib, a BRAF kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment of BRAF-mutant melanoma, demonstrated clinical benefit for 3 patients with BRAFV600E mutation-positive papillary thyroid cancer in a phase 1 trial. Researchers evaluated the activity of vemurafenib in this patient population in a phase 2 study.

Fifty-one patients were enrolled with recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine that tested positive for the BRAF V600E mutation. Patients who had not received a multikinase inhibitor targeting VEGFR were assigned to cohort 1 and patients who were previously treated with 1 were assigned to cohort 2; all participants received vemurafenib 960 mg orally twice daily.

After a median follow-up of 18.8 months in cohort 1, results showed that the best overall response rate was 38.5% (95% CI, 20.2-59.4), all of which were partial responses.

Sixty-five percent of patients in cohort 1 and 68% of those in cohort 2 experienced grade 3 to 4 adverse events. The most common grade 3 to 4 adverse events were squamous cell carcinoma of the skin, lymphopenia, and increased γ-glutamyltransferase.

RELATED: Papillary Thyroid Cancer: Radiographic SLNB May Lead to Management Change

Serious adverse events were reported in 62% and 68% of patients in cohorts 1 and 2, respectively.

The findings suggest that vemurafenib represents a potential new therapeutic option for this patient population. These results warrant a phase 3 trial.                 

Reference

  1. Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Jul 22. doi: 10.1016/S1470-2045(16)30166-8. [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs